Daily Stock List
Bralorne Gold Mines Ltd. (BPMSF)
BabyBulls reported earlier on Bralorne Gold Mines Ltd. (BPMSF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Vancouver, British Columbia, Bralorne Gold Mines Ltd. engages in the acquisition, exploration, and development of natural resource properties in Canada. An exploration stage enterprise, the Company is currently operating at 100 tons per day. Bralorne Gold Mines acquired all the claims of the Bralorne, King, and Pioneer mines plus surrounding new ground in southwest British Columbia. These holdings represent the first time in history that all three operations and important additional claims have been held by one company. These three historic mines represent the largest historic gold producer in the Canadian Cordillera producing 4.1 million ounces of gold. Bralorne Gold Mines lists on the OTCQX International.
The currently targeted areas between the Bralorne, King, and Pioneer mines were claim gaps that were not explored during the life of the historic mines but are now part of the 2,500 hectare property. Since start-up in May of 2011, an estimated 7,642 ounces of gold have been produced from 28,800 tonnes at an average head grade of 9.12 grams gold per tonne. Bralorne is continuing to explore and mine; the Company plans to increase production in stages over the coming years, with an ultimate goal of 500 tonnes per day.
Yesterday, Bralorne Gold Mines provided an update of activities at their Bralorne mining operation located near Gold Bridge, British Columbia. The 2012 underground drill program is focusing on the under-explored BK gap area located between the historic Bralorne and King mines. The 2012 underground drill program has completed 15 holes (1,935 m) to date.
The primary objective of the program is to test for extensions of high grade gold mineralization previously discovered in the BK-3 Zone, where underground drifting previously reported results of 68.7 grams gold per tonne (un-cut) over 0.8 meters (true thickness) along a 160 meter strike length. The most recent hole (UB12-015) intersected a quartz vein interval that contains a number of grains of visible gold and assayed 385.57 grams gold per tonne (uncut) over 1.2 meters. This will be investigated by sub-level drifting in the coming months. Additionally, Bralorne recently started surface exploration drilling in the Bralorne-Pioneer gap area after receiving their permit.
Bralorne Gold Mines Ltd. (BPMSF), closed Tuesday’s session at $0.739, down 8.43%, on 200 volume with 1 trade. The average volume for the last 60 days is 2,145 and the stock's 52-week low/high is $0.672/$1.17.
InVivo Therapeutics Holdings Corp. (NVIV)
Real Pennies, OTC Stock Review, and TheStockAdvisor reported earlier on InVivo Therapeutics Holdings Corp. (NVIV), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2005 and listed on the OTC Bulletin Board, InVivo Therapeutics Holdings Corp. is a developer of innovative technologies for the treatment of Spinal Cord Injuries (SCI) and neurotrauma. The Company is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The Company was founded based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. InVivo Therapeutics has their headquarters in Cambridge, Massachusetts.
In 2011, InVivo Therapeutics earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association. This was for the Company’s outstanding contribution to spinal cord injury medicine. InVivo’s technologies includes multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs).
The Company’s intention is to take advantage of their platform technology to deliver several products to the market. These include a biocompatible polymer scaffolding device to treat acute SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI, and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI.
Last week, InVivo Therapeutics hosted a ribbon cutting ceremony for the Company’s new office, manufacturing, and lab space at One Kendall Square, Building 1400 in Cambridge, Massachusetts. The 21,000 square foot facility will serve as the new headquarters for InVivo, consolidating all of their operations.
Last Friday, InVivo Therapeutics announced the appointment of Mr. Bill D'Agostino as Senior Director of Manufacturing & Engineering. Mr. D'Agostino joins InVivo following fifteen years at Covidien and, most recently, seven years at Angiotech Pharmaceuticals as Vice President, Engineering. Mr. D’Agostino, in his career so far, has launched over 100 new polymer products including families of biodegradable sutures.
InVivo Therapeutics Holdings Corp. (NVIV), closed Tuesday’s session at $1.50, up 5.63%, on 177,974 volume with 144 trades. The average volume for the last 60 days is 138,978 and the stock's 52-week low/high is $0.60/$3.23.
Bonso Electronics International, Inc. (BNSO)
Wall Street Greek reported previously on Bonso Electronics International, Inc. (BNSO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Bonso Electronics International, Inc. is a designer and manufacturer of sensor based products. The Company designs, develops, manufactures, assembles, and markets a wide-ranging line of electronic scales, weighing instruments, health care products, and telecommunications products. Their products are manufactured in the People's Republic of China (PRC) for customers primarily located in North America and Europe.
In 1980, Bonso established with headquarters in Hong Kong. In
1987, they started production in China. In 1989, Bonso Electronics was listed in the U.S., with their common stock trading on the NASDAQ. Listed on the NASDAQ Capital Market, Bonso Electronics International has their Shenzhen factory in Fu Yong, Shenzhen, China, and their Xinxing Factory in Xinxing, Yunfu City, Guangdong, China.
The Company’s services include product design and prototyping, production tooling, procurement of components, total quality management, and just-in-time (JIT) delivery. In addition, Bonso Electronics independently designs and develops electronic products for private label markets.
Bonso Electronics designs and manufactures sensor based scales and telecommunications products on an OEM/ODM basis. The Company’s products include two-way radios, cordless phones, bathroom scales, body fat scales, kitchen scales, postal scales, laboratory scales, pocket scales, and industrial scales used in consumer, commercial, and industrial applications for worldwide markets.
Last Friday, Bonso Electronics International reported their financial results for the fiscal year ended March 31, 2012. They reported a net loss for the fiscal year ended March 31, 2012, of $0.9 million or $0.17 basic and diluted loss per share. Net sales for the fiscal year ended March 31, 2012 decreased 6.0 percent to $26.7 million from $28.4 million for the fiscal year ended March 31, 2011.
Mr. Anthony So, Chairman of Bonso Electronics International, stated, "Our operations in China continue to be affected by inflation, especially increase in labor costs due to the annual raise of minimum wage by the local government. However, we are pleased to announce that the gross margin as a percentage of revenue increased to approximately 14.6 percent during the fiscal year ended March 31, 2012, as compared to approximately 12.8 percent during the fiscal year ended March 31, 2011. The higher gross margin was the result of the reduced manufacturing cost due to increase in efficiency."
Bonso Electronics International, Inc. (BNSO), closed Tuesday’s session at $1.01, up 4.12%, on 31,099 volume with 7 trades. The average volume for the last 60 days is 1,508 and the stock's 52-week low/high is $0.8829/$1.88.
CombiMatrix Corp. (CBMX)
SmarTrend Newsletters reported earlier on CombiMatrix Corp. (CBMX), AllPennyStocks did previously, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 1995, CombiMatrix Corp., by way of their wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric, and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR, as well as G-Band Chromosome Analysis. The Company looks for strategic partnerships. They seek affiliations with other laboratories and pathology groups that would like to offer the Company’s testing services to their own physician and patient populations. CombiMatrix is based in Irvine, California.
The Company’s CMDX subsidiary offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can undergo identification through conventional technologies. CMDX was also the first commercial clinical laboratory in the U.S to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals.
CombiMatrix is a CLIA-certified & CAP accredited commercial clinical laboratory. The Company’s customers include healthcare institutions, such as hospitals and clinics, physicians, and individual patients; and organizations, such as commercial insurance companies, as well as government payors, including Medicare and Medicaid.
CombiMatrix has established their company as an industry leader in microarray-based clinical testing. They have accomplished this by their core team of arrayCGH-pioneering physicians, scientists, and technicians and their commitment to client and patient-focused service. The Company’s oncology diagnostic tests include DNAarrayHeme Profile test, which addresses common hematological malignancies with an emphasis on chronic lymphocytic leukemia; DNAarrayHER2 PRO, which determines HER2 status; and DNAarrayTumor Profile for DNA-based genomic analysis of solid tumors.
In August, CombiMatrix reported that total revenues for the second quarter and first six months of 2012 increased to a record $1.3 million and $2.6 million, respectively, up 6 percent and 19 percent from the second quarter and first six months of 2011. Revenues from their core prenatal testing markets in the second quarter grew by 48 percent over the corresponding period in 2011 and grew by over 77 percent in the first six months of the year over the prior year period.
Yesterday, CombiMatrix announced that they entered into an agreement to issue securities in a private placement transaction to certain accredited investors that will result in proceeds to the Company totaling $2.5 million, to be received in two tranches. The financing is through the sale of convertible preferred stock.
CombiMatrix Corp. (CBMX), closed Tuesday’s session at $0.60, down 0.38%, on 11,935 volume with 10 trades. The average volume for the last 60 days is 8,143 and the stock's 52-week low/high is $0.5625/$2.65.
Inuvo, Inc. (INUV)
Stock Traders Chat, PennyOmega, and Stock Fortune Teller reported previously on Inuvo, Inc. (INUV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Inuvo, Inc. is an Internet marketing and technology company with corporate headquarters in New York City. The Company specializes in marketing browser-based consumer applications, managing networks of website publishers, and operating specialty websites. Inuvo’s shares trade on the NYSE Amex. The Company formerly went by the name Kowabunga! Inc. They changed their name to Inuvo, Inc. in July of 2009.
The Company’s solutions help advertisers drive targeted transactions and acquire customers either on a pay-per-click (PPC), pay-per-lead or pay-per-sale basis by way of a variety of marketing channels.
The Inuvo Platform is the data hub for all of the Company’s transactions, products, and services.
This solution gives advertisers the ability to create and manage their own campaigns. This solution provides web publishers with more effective ways to monetize their advertising inventory. Moreover, strategic partners and web developers may customize their implementation and services through an application-programming interface (API).
Inuvo Search is an exclusive program allowing approved publishers operating shopping search engines, local search engines, niche directory sites, and other search-related sites to have PPC sponsored ads on their site. Inuvo’s Affiliate Marketing enables advertisers and publishers to work together with a shared purpose of getting the advertiser more leads, sales, or clicks to their website.
Concerning brands, the Company’s Kowabunga® is a daily deal website. It aggregates the best consumer deals from various deal websites. It also includes their Kowabunga exclusives. Inuvo’s BargainMatch® offers consumers a comparison shopping experience for millions of products from thousands of stores. It incentivizes users with cash-back opportunities on purchases made. BargainMatch.com uses the Inuvo App, BargainMatch. BargainMatch.com aggregates product, price, as well as coupons across the leading shopping comparison engines to empower the consumer.
The Company’s Yellowise® is a local business directory. It is used to find business listings anywhere in the U.S. through a simple and quick search, inclusive of user reviews. Inuvo also offers their ALOT portfolio of products. Through the ALOT portfolio, millions of consumers discover applications which display through the ALOT Appbar, ALOT Toolbar, and ALOT Home. Inuvo also has their BabytoBee®. This is a marketing platform designed to reach and engage pre- and postnatal mothers.
Yesterday, Inuvo announced that they were invited to present at the 5th Annual LD Micro Conference in Los Angeles, California on Thursday, October 4, 2012 at 11:00 AM PST/2:00 PM EST. Mr. Peter Corrao, Chief Executive Officer of Inuvo, will provide a brief update on the Company and participate in a question and answer segment with interested parties.
Inuvo, Inc. (INUV), closed Tuesday’s session at $0.8602, up 3.64%, on 297,152 volume with 346 trades. The average volume for the last 60 days is 51,124 and the stock's 52-week low/high is $0.40/$1.94.
WPCS International, Inc. (WPCS)
SmarTrend Newsletters reported recently on WPCS International, Inc. (WPCS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
WPCS International, Inc. is a design-build engineering company that lists on the NASDAQ Capital Market. The Company focuses on the implementation requirements of communications infrastructure. They provide their engineering capabilities including wireless communication, specialty construction, and electrical power to the public services, healthcare, energy, and corporate enterprise markets around the world.
WPCS International has their corporate headquarters in Exton, Pennsylvania. The Company has domestic operations offices in Redmond, Washington; Suisun City, California, and Monroe Township, New Jersey. WPCS has international operations offices in Taian, Shandong, China, and Woombye, Queensland, Australia.
Concerning Wireless Communication, WPCS can design a client’s wireless network and provide the technology integration necessary to meet goals for enhanced communication, increased productivity, and reduced costs. Concerning Specialty Construction, the Company designs and deploys renewable energy solutions, and supports companies that desire to maximize the efficiency of their energy supply infrastructure by providing a range of pipeline trenching solutions.
Concerning Electrical Power, WPCS provides integrated solutions; technology convergence is their specialty. They create integrated building systems, including the installation of advanced structured cabling systems and electrical networks. The Company supports the integration of telecommunications, fire protection, security, as well as HVAC in an environmentally safe manner. Furthermore, WPCS designs for the future. They do this through building in capacity for expansion as new capabilities are added.
In September, WPCS International announced financial results for the fiscal year 2013 first quarter ended July 31, 2012. In the first quarter, the WPCS domestic and international operation centers generated EBITDA of approximately $695,000. This is compared to an EBITDA loss of $7.1 million in the preceding quarter ended April 30, 2012. These same operation centers generated EBITDA of $2.0 million for the same period in the year ago period.
WPCS reported net income of approximately $994,000 or $0.14 per diluted shared. This includes income from discontinued operations of approximately $1.7 million, or $0.24 per diluted share related to the asset sales of their Hartford and Lakewood Operations. This compares to a net loss of approximately $35,000 or $0.01 per diluted share for the same period a year prior, which includes a loss from discontinued operations of approximately $189,000, or $0.03 per diluted share. For the first quarter, WPCS reported revenue of $13.4 million compared to $18.6 million for the same period in the prior year.
WPCS International, Inc. (WPCS), closed Tuesday’s session at $0.55, up 22.22%, on 203,153 volume with 523 trades. The average volume for the last 60 days is 24,977 and the stock's 52-week low/high is $0.37/$0.8839.
Integrated Environmental Technologies Ltd. (IEVM)
Momentum Traders, HotStockChat, SmallCapVoice, Stock Guru, and OTC Picks reported previously on Integrated Environmental Technologies Ltd. (IEVM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Little River, South Carolina, Integrated Environmental Technologies Ltd. operates via their wholly-owned operating subsidiary; I.E.T., Inc. The Company’s EcaFlo® Division designs, manufactures, markets, sells, and installs proprietary Electro-Chemical Activation (ECA) equipment in the U.S. and globally. The Essential Oils Division offers a cost effective, safe, efficient and premier method of obtaining bioactive compounds and oils from plants. Integrated Environmental Technologies sells a disinfecting solution under the EcaFlo® and Excelyte® brand names and sells a cleaning solution under the Catholyte Zero™ brand name. Integrated Environmental Technologies’ shares trade on the OTC Bulletin Board.
Both of the Company’s solutions are produced by their proprietary EcaFlo® equipment. This EcaFlo® equipment utilizes an electrolytic process known as electrochemical activation to reliably produce environmentally responsible solutions for cleaning, sanitizing, as well as disinfecting. EcaFlo® Anolyte and Excelyte® solutions are EPA-registered surface disinfectants and sanitizers approved for hospital-level use. The products can be used safely anywhere there is a need to control pathogens, bacteria, viruses, and germs. Catholyte Zero™ solutions are an environmentally friendly cleanser and degreaser for janitorial, sanitation, and food processing uses.
Integrated Environmental Technologies’ 14,000 square foot production facility is where they design and assemble equipment that utilizes unique technologies, producing products that have been tested, proven, and accepted by private, state, and federal agencies. The Company has approval by the US Food and Drug Administration (FDA) for applications of their proprietary extraction technology that is undergoing introduction into the healthcare, medical, nutraceutical, and pharmaceutical markets.
Last week, Integrated Environmental Technologies announced that Sky Blue Industries, Inc. added the Company's Excelyte® disinfecting solution and Catholyte Zero™ cleaning solutions to the Sky Blue product offerings. Sky Blue is a manufacturer and distributor of chemicals; they provide services to all aspects of the transportation and auto care industries. Sky Blue's customers include regional/national auto and truck rental fleets, national transport carriers, transportation maintenance facilities; car dealerships and fast lube shops. Sky Blue mainly distributes products in Utah, Idaho, Nevada, Wyoming, and Montana.
Integrated Environmental Technologies Ltd. (IEVM), closed Tuesday’s session at $0.06, down 1.64%, on 231,500 volume with 4 trades. The average volume for the last 60 days is 40,702 and the stock's 52-week low/high is $0.04/$0.09.
Augme Technologies, Inc. (AUGT)
PennyTrader Publisher and SmarTrend Newsletters reported recently on Augme Technologies, Inc. (AUGT), Real Pennies, MicroCap Gems, Money Morning did earlier, and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCBB, Augme Technologies, Inc. provides strategic services and mobile marketing technology to leading consumer and healthcare brands. The Company’s offerings allow marketers, brands, and agencies the ability to plan, create, test, deploy, and track mobile marketing programs across every mobile channel. These include SMS, 2D/QR codes, mobile websites, advertising networks, social media, and branded apps. Augme Technologies has their corporate headquarters in New York, New York. The Company has operations in Seattle, Atlanta, Dallas, Los Angeles, Chicago, Tucson, and London.
Augme Technologies’ platforms facilitate consumer brand interaction and the ability to track and analyze campaign results. Utilizing their patented device-detection and proprietary mobile content adaptation software, AD LIFE® solves the mobile marketing industry problem of disparate operating systems, device types, and on-screen mobile content rendering.
In addition, the Company provides business to consumer (B2C) utilities. These include national mobile couponing solutions, strategic mobile healthcare tools, custom mobile application development, and consumer data tracking and analytics. Augme also owns Hipcricket and licenses the digital broadcast platform BOOMBOX®.
Augme Technologies patent portfolio presently covers technology inventions from 1999 to 2033 and protects technology that enables the customized content delivery to any Internet enabled device; device, browser, software, and profile detection with content targeting; content targeting based on profiles and ambient conditions; and content targeting based on profiles within virtual environments. The Company owns 13 patents; it has an additional 80 patents pending with the United States Patent & Trademark Office (USPTO). Augme owns four international patents pending.
Last Friday, Augme Technologies announced that they priced an underwritten public offering of 8,500,000 shares of their common stock together with warrants to purchase an additional 2,125,000 shares of common stock. Each share of stock and warrant will be sold at a price to the public of $0.80, for gross proceeds of approximately $6.8 million. The net proceeds from the sale of the securities will be approximately $6.132 million. Augme also granted to the underwriter a 45-day option to purchase from the Company up to 1,275,000 additional shares of common stock and warrants for the purchase of 318,750 shares of common stock to cover any over-allotments. Augme currently intends to use the net proceeds from this offering for organic expansion in existing and new markets, for general corporate purposes, and to pay debt in the amount of $200,000. The expectation is that the offering will close on or about October 3, 2012.
Augme Technologies, Inc. (AUGT), closed Tuesday’s session at $0.77, up 3.94%, on 392,418 volume with 156 trades. The average volume for the last 60 days is 432,571 and the stock's 52-week low/high is $0.67/$3.15.
Teletouch Communications, Inc. (TLLE)
The QualityStocks Daily Newsletter would like to spotlight Teletouch Communications, Inc. (TLLE). Today, Teletouch Communications, Inc. closed trading at $0.4990, even with yesterday's close, on 24,800 volume with 10 trades. The stock’s average daily volume over the past 60 days is 26,311, and its 52-week low/high is $0.253/$0.89.
Teletouch Communications, Inc. reported that the company will be returning for the 7th year as the Official Cellular Sponsor of the 10th anniversary Bell Helicopter Armed Forces Bowl, this December 29, 2012. Teletouch-Hawk Electronics will host their usual free Global Calling and Photo Center for visiting troops attending and this exciting post-season matchup will pit qualifying teams from the Mountain West Conference and Conference USA NCAA divisions, all televised live by ESPN and heard on ESPN Radio from TCU’s $164M renovated Amon G. Carter Stadium in Fort Worth, Texas.
Teletouch Communications, Inc. (TLLE) offers a comprehensive suite of wireless telecommunications solutions, including cellular, GPS-telemetry, and wireless messaging. Founded in 1964, the company provides its products and services to consumers, businesses, and government agencies, operating a chain of 11 retail and authorized agent stores, in conjunction with its direct sales force, call center operations, and various retail eCommerce websites.
Through its wholly owned subsidiary, Progressive Concepts, Teletouch operates a national distribution business, PCI Wholesale, primarily serving Tier-1 (AT&T, T-Mobile, Verizon, Sprint) cellular carrier agents, Tier-2, Tier-3, and rural carriers, as well as auto dealers and smaller consumer electronics retailers. The subsidiary's international sales coverage includes Canada, Mexico, Brazil, Singapore, and China.
The company is currently focusing on growing its core wholesale distribution business. The business plan being executed includes selling non-core corporate assets and reviewing potential acquisition opportunities. Operators and retailers of all sizes are seeking new sources of revenue at lower costs, creating a large opportunity to provide great products and value-added distribution capabilities at competitive prices.
Teletouch's management team has extensive experience in financing, acquiring, and operating retail, wireless and other related companies. Robert McMurrey, Chairman and CEO, guided Teletouch's original external expansion with the completion of over 15 acquisitions to date. Today, the company supports over 60,000 wireless customers, leveraging its long-standing relationships and global presence to drive future earnings growth. Disclaimer
Teletouch Communications, Inc. Blog
Teletouch Communications, Inc. News:
Teletouch Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
Teletouch Announces Distribution Agreement with Unimax Communications for Sales of UMX Branded Cellular Handsets in North America
Teletouch Reports Fiscal Year 2012 Results
MusclePharm Corp. (MSLP)
The QualityStocks Daily Newsletter would like to spotlight MusclePharm Corp. (MSLP). Today, MusclePharm Corp. closed trading at $0.0058, off by 3.33%, on 7,957,470 volume with 65 trades. The stock’s average daily volume over the past 60 days is 4,640,477, and its 52-week low/high is $0.0055/$0.0375.
MusclePharm Corp. (MSLP) is focused on providing a full line of Informed Choice-approved nutritional supplements that not use any substances banned in the sports industry. Now sold in more than 120 countries and available in over 10,000 U.S. retail outlets, the company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen.
Current CEO Brad Pyatt founded the company to develop a superior line of nutritional supplements that would help fellow athletes improve their performance in a way that existing supplements did not. Even as the company has grown, its mission has remained the same: to improve its customers' lives, increase their ability to excel, use cutting-edge science to develop the best nutritional supplements on the market, and provide a safe option for athletes.
MusclePharm's products were developed through exhaustive research at the MusclePharm Sports Science Center Research Institute. New products are created through a six-stage research protocol that involves the expertise of top nutritional scientists. Before launching a product, the company conducts field testing using a pool of over one hundred elite professional athletes from various professional sports leagues, including the National Football League, Mixed Martial Arts, and Major League Baseball.
Over the last few years, the consumption of sports nutrition products has shifted to mainstream consumers who have become the key drivers of growth within the industry. Teenagers and college students, women, and even older individuals are now using these products to help them live a more active and healthier lifestyle. With a full line of supplements and an extensive distribution network, MusclePharm is well positioned to capitalize on the growing demand. Disclaimer
MusclePharm Corp. Company Blog
MusclePharm Corp. News:
MusclePharm Adds Dick's Sporting Goods To Its Growing Retail Distribution
United States Sports Academy Researchers Present Clinical Trial Results For MusclePharms' Assault™ Pre-Workout
MusclePharm Announces Board Changes, Expansion
Skinny Nutritional Corp. (SKNY)
The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.004, even for the day, on 348,181 volume with 7 trades. The stock’s average daily volume over the past 60 days is 1,523,313, and its 52-week low/high is $0.003/$0.041.
Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.
The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.
The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.
Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer
Skinny Nutritional Corp. Blog
Skinny Nutritional Corp. News:
Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration
Skinny Nutritional Corp. Enters Into $15M Financing, Positions Company to Grow Skinny Brand Portfolio Nationally
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, even for the day, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 28, and its 52-week low/high is $0.80/$0.80.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund
VistaGen CEO Issues Update Letter to Stockholders
VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity
Teletouch Communications, a leading U.S. wireless services, cellular, and consumer electronics distributor, announced that it will be the Official Cellular Sponsor of the 10th anniversary Bell Helicopter Armed Forces Bowl, being played on Saturday, December 29, 2012, at 10:45 a.m. Central. The post-season game will feature qualifying teams from the Mountain West Conference and Conference USA NCAA divisions and will be televised by ESPN and heard on ESPN Radio broadcasting from the recently renovated Amon G. Carter Stadium in Fort Worth, Texas.
Returning for the 7th year as the Official Cellular Sponsor, Teletouch-Hawk Electronics will once again host a free Global Calling and Photo Center for visiting troops attending the game. Men and women of the armed forces will be able to call and send professionally made photos to their friends and family across the globe, at no cost to them. This service has proved very popular with the troops each year.
“We appreciate what Teletouch-Hawk Electronics once again brings to our game,” stated Brant Ringler, executive director of the Bell Helicopter Armed Forces Bowl. “Providing the opportunity for our warriors to communicate with and send pictures to their friends and loved ones anywhere in the world during the holiday season is just a small ‘thank you’ for their dedicated service to our country, and represents what the Bell Helicopter Armed Forces Bowl is all about.”
“We are proud to once again be part of this great team of ESPN partners that honor our men and women in uniform,” added T. A. ‘Kip’ Hyde, Jr., Teletouch President and Chief Operating Officer. “With several thousand expected active military, reserve and wounded warrior guests, we are pleased to be able to provide our free calling and photo center. There is no better way to ring in the New Year than by watching a great football game and honoring our great American heroes.”
Owned and operated by ESPN Regional Television, the Bell Helicopter Armed Forces Bowl has featured the “armed forces” theme for 6 years now. Patriotic overtones recognizing all five branches of the service are prevalent throughout the game. Past Bell Helicopter Armed Forces Bowls have included fan-fest areas showcasing armed forces hardware, flyovers, demonstrations by several of the military’s top skydiving teams, the awarding of custom homes to wounded warriors, on-field induction ceremonies, armed forces bands and honor guards, the Teletouch-Hawk Electronics Free Global Calling & Photo Center, and the awarding of the annual “Great American Patriot Award” presented by Armed Forces Insurance.
For more information about the Bell Helicopter Armed Forces Bowl, visit ArmedForcesBowl.com, Facebook.com/ArmedForcesBowl or Twitter.com/ArmedForcesBowl.
MusclePharm, fast growing maker of science-based nutritionals for athletes, is proud of the fact that it works with researchers, doctors, and professional athletes to determine the optimum formulations for top athletic performance, and has signed key endorsement agreements to emphasize its ties to the athletic community. Here are just a few members of the MusclePharm team:
• Michael Vick – Quarterback, Philadelphia Eagles. Four-time Pro Bowl selection. Only quarterback in NFL history to rush for over 1000 yards during the regular season. During his freshman year of college, he placed third in the Heisman rankings. In the NFL, he ranks second among quarterbacks in career rushing yards. Mike is committed to staying on the edge of fitness.
• Patrick Willis – Linebacker with the San Francisco 49ers, he’s 2X All-American, Butkus Award Winner, Five-time Pro Bowl selection, 3-time AP All-Pro First Team selection. In college, he was named SEC Defensive Player of The Year.
• Louie Simmons – Proving that top fitness can be maintained throughout life, Louie Simmons benched 600 at age 60, and is the only lifter over 50 to squat 920 and total 2100. Louie created Westside Barbell, a gym that separates true lifters from everyone else. To date, WSB has 27 lifters who have totaled more than 2000. Louie has also published over 100 articles and produced seven training videos. Strength consultant for numerous Professional and College athletic programs, Simmons is one of only six athletes in the world to hit Elite in five weight classes and has been totaling Elite for over 40 years.
• Lind Walter – World recognized weight trainer and fitness champion. Philadelphia Classic, 1st Juniors, 1st Open Light Heavy, Certified Trainer – Contest Prep, Nutrition, Weight Management. At 15, Lind began weight training to prepare for football. In a few months, not only was he the strongest kid on the team, but he set every school lifting record. In college, Lind learned all he could about Human Anatomy, Bio Mechanics, and Nutrition. He competed in his first competition in 2005, and won three classes. Today Lind is a well-recognized face in the fitness industry and a respected trainer.
Such agreements are critical for marketing, supporting MusclePharm distributors and retailers. All the research in the world isn’t any good without getting the word out. MusclePharm feels it has hit upon a winning strategy: The company has invested heavily in research and testing, verifying the effectiveness of its products and thereby clearly differentiating itself. Backing this up with links to top athletes is a marketplace one-two punch, and one of the key reasons for the company’s rapid expansion.
For additional information, visit the company’s website at www.MusclePharm.com
First Financial Service recently announced the retirement of Senator Walter Dee Huddleston, director of the company and its banking subsidiary, First Federal Savings Bank of Elizabethtown, Inc. Senator Huddleston’s retirement was effective as of September 19, 2012. His retirement brings an end to over 46 years of service to the organization, including 15 years as Chairman; he will remain a part of the organization as a Director Emeritus.
Senator Huddleston is a former two-term member of the U.S. Senate. He began his professional career in broadcasting in Elizabethtown, Kentucky, and today he owns and operates Walter D. Huddleston Consulting, a legislative consulting firm located in Elizabethtown and Washington D.C. Senator Huddleston has received the U.S. Central Intelligence Agency Medal of Honor and awards as the Outstanding Young Man of Elizabethtown and Kentucky. He recently was inducted into the Kentucky Civil Rights Hall of Fame as well.
Current Chairman of Boards, Steve Mouser, remarked, “Senator Huddleston’s commitment and contributions to our organization for over four decades will be missed. However, we are very pleased that he will remain with the organization as a Director Emeritus.”
First Financial also announced the appointment of Mr. Gregory S. Schreacke to the board of directors the company and its subsidiary. A licensed CPA, Mr. Schreacke joined the organization as the company’s CFO in January 2004, serving in that capacity until 2008 when he was promoted to President of the company and First Federal. He assumed principal management responsibility for the Company and First Federal in February 2012.
“We are fortunate to have Greg join the board of directors,” said Mouser, current Chairman of the Boards. “We have great confidence in his ability and look forward to working with him as a board member and as the leader of this organization for years to come.”
CytRx, a biopharmaceutical company that specializes in oncology, yesterday announced favorable data from its Phase 1b/2 clinical trial of its doxorubicin conjugate aldoxorubicin (previously INNO-206), a treatment designed to target and combat tumors. The favorable results from its trial in patients with an advanced form of soft tissue sarcoma was presented at the Sarcoma Poster-Discussion Session (Hall H) at the European Society of Medical Oncology (ESMO) 2012 Congress in Vienna, Austria. Renowned sarcoma specialist, Sant P. Chawla, M.D., Director of the Sarcoma Oncology Center in Santa Monica, CA, led the presentation, entitled “INNO-206 (aldoxorubicin) Is An Active Drug For Relapsed Soft Tissue Sarcoma.”
The aldoxorubicin Phase 1b/2 clinical trial data showed “clinical benefit” (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) for those patients that received the maximum tolerated dose of aldoxorubicin. Of evaluable patients, all of whom suffer from relapsed or refractory soft tissue sarcoma, 10 in 13 (77%) exhibited signs of clinical benefit. The first of this data was presented on June 3, 2012, at the ASCO (American Society of Clinical Oncology) Conference.
Steven A. Kriegsman, CEO and President of CytRx said, “These clinical trial results with aldoxorubicin were introduced at ASCO, presented today at ESMO, and will be featured at the Connective Tissue Oncology Society (CTOS) Conference in Prague, Czech Republic, in November. We believe that the avid reception for presentation of the aldoxorubicin clinical data by leading oncology conferences is a testament to their importance and we are pleased that these clinical results are capturing the attention of the oncology community.”
“Although the trial data are derived from a small patient group, the fact that clinical benefit was seen in 77% of these patients is noteworthy, particularly given the advanced stage of disease,” said the clinical trial’s principal investigator and renowned sarcoma expert Sant P. Chawla, M.D., F.R.A.C.P. “Further, of the eight evaluable patients who were previously treated with doxorubicin and had either not responded or relapsed, five showed clinical benefit with aldoxorubicin. Among these, three showed prolonged partial responses with greater than 30% tumor shrinkage.”
Aldoxorubicin works by combining doxorubicin, a commonly used chemotherapeutic agent, with a proprietary linker technology. Because doxorubicin has an inherent toxicity level, patients are limited to specific doses to protect them from overexposure. However, because the linker technology delivers doxorubicin to tumor sites (where the delivery molecule is cleaved and the doxorubicin is released), the potential exists to increase the drug’s efficacy, while avoiding many of the associated side effects.
CytRx Corporation has plans to meet with the FDA during the second half of 2012 to discuss a potential Phase 3 pivotal trial for patients who have since relapsed or were refractory to chemotherapy.
Today's Top 3
The QualityStocks Public Company Sponsor News